Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
Roche (RHHBY) has announced the launch of the Roche Genentech Innovation Center Boston at Harvard's Enterprise Research Campus in Allston. The center will focus on Cardiovascular, Renal, and Metabolism (CVRM) research, along with AI and data science initiatives to accelerate drug discovery.
Starting with a 30,000 square feet lease, Roche plans to expand its R&D presence to accommodate up to 500 employees. The center will be led by Manu Chakravarthy, SVP and Global Head of CVRM Product Development.
This investment builds upon Roche's existing presence in the US, where the company has invested USD 11 billion over the past decade and employs over 25,000 people across multiple Genentech and Diagnostics sites. The new facility represents Roche's commitment to strengthening its long-standing partnership with Harvard University and expanding its footprint in the Boston healthcare ecosystem.
Roche (RHHBY) ha annunciato l'apertura del Roche Genentech Innovation Center di Boston presso il Campus di Ricerca dell'Enterprise di Harvard ad Allston. Il centro si concentrerà sulla ricerca in Cardiovascolare, Renale e Metabolismo (CVRM), insieme a iniziative di intelligenza artificiale e scienza dei dati per accelerare la scoperta di farmaci.
Inizialmente con un affitto di 30.000 piedi quadrati, Roche prevede di espandere la propria presenza in R&D per ospitare fino a 500 dipendenti. Il centro sarà guidato da Manu Chakravarthy, SVP e Responsabile Globale dello Sviluppo Prodotti CVRM.
Questo investimento si basa sulla presenza già esistente di Roche negli Stati Uniti, dove l'azienda ha investito 11 miliardi di dollari USA nell'ultimo decennio e impiega oltre 25.000 persone in diversi siti Genentech e Diagnostica. La nuova struttura rappresenta l'impegno di Roche a rafforzare la sua storica partnership con l'Università di Harvard e ad espandere la sua presenza nell'ecosistema sanitario di Boston.
Roche (RHHBY) ha anunciado la apertura del Centro de Innovación Roche Genentech en Boston en el Campus de Investigación Empresarial de Harvard en Allston. El centro se enfocará en la investigación Cardiovascular, Renal y Metabolismo (CVRM), junto con iniciativas de inteligencia artificial y ciencia de datos para acelerar el descubrimiento de fármacos.
Comenzando con un alquiler de 30,000 pies cuadrados, Roche planea expandir su presencia en I+D para acomodar hasta 500 empleados. El centro será dirigido por Manu Chakravarthy, SVP y Jefe Global de Desarrollo de Productos CVRM.
Esta inversión se basa en la presencia existente de Roche en los EE. UU., donde la compañía ha invertido 11 mil millones de dólares en la última década y emplea a más de 25,000 personas en múltiples sitios de Genentech y Diagnósticos. La nueva instalación representa el compromiso de Roche de fortalecer su asociación de larga data con la Universidad de Harvard y expandir su huella en el ecosistema de salud de Boston.
로슈 (RHHBY)는 올스턴에 위치한 하버드 기업 연구 캠퍼스에 로슈 제넨텍 혁신 센터 보스턴을 개소한다고 발표했습니다. 이 센터는 심혈관, 신장 및 대사(CVRM) 연구와 함께 인공지능 및 데이터 과학 이니셔티브를 통해 약물 발견을 가속화하는 데 중점을 둘 것입니다.
30,000 평방피트 임대 계약으로 시작하여, 로슈는 최대 500명의 직원을 수용하기 위해 R&D 존재를 확장할 계획입니다. 이 센터는 CVRM 제품 개발의 글로벌 책임자인 Manu Chakravarthy가 이끌게 됩니다.
이번 투자는 로슈가 미국에 이미 존재하는 기반 위에 세운 것으로, 지난 10년 동안 110억 달러를 투자하고 있으며, 여러 제넨텍 및 진단 사이트에서 25,000명 이상의 직원을 고용하고 있습니다. 새로운 시설은 하버드 대학교와의 오랜 파트너십을 강화하고 보스턴 의료 생태계에서의 입지를 확장하려는 로슈의 의지를 나타냅니다.
Roche (RHHBY) a annoncé l'ouverture du Centre d'Innovation Roche Genentech à Boston sur le Campus de Recherche d'Entreprise de Harvard à Allston. Le centre se concentrera sur la recherche en Cardiovasculaire, Rénal et Métabolisme (CVRM), ainsi que sur des initiatives d'intelligence artificielle et de science des données pour accélérer la découverte de médicaments.
Commençant par un bail de 30 000 pieds carrés, Roche prévoit d'étendre sa présence en R&D pour accueillir jusqu'à 500 employés. Le centre sera dirigé par Manu Chakravarthy, SVP et Responsable Mondial du Développement de Produits CVRM.
Cette investissement s'appuie sur la présence existante de Roche aux États-Unis, où l'entreprise a investi 11 milliards USD au cours de la dernière décennie et emploie plus de 25 000 personnes sur plusieurs sites Genentech et Diagnostics. La nouvelle installation représente l'engagement de Roche à renforcer son partenariat de longue date avec l'Université de Harvard et à élargir son empreinte dans l'écosystème de santé de Boston.
Roche (RHHBY) hat die Eröffnung des Roche Genentech Innovationszentrums in Boston auf dem Enterprise Research Campus der Harvard University in Allston angekündigt. Das Zentrum wird sich auf die Forschung in den Bereichen Herz-Kreislauf, Nieren und Stoffwechsel (CVRM) konzentrieren, sowie auf KI- und Datenwissenschaftsinitiativen zur Beschleunigung der Arzneimittelentdeckung.
Beginnend mit einem 30.000 Quadratfuß großen Mietvertrag plant Roche, seine F&E-Präsenz auszuweiten, um bis zu 500 Mitarbeiter unterzubringen. Das Zentrum wird von Manu Chakravarthy, SVP und Global Head of CVRM Product Development, geleitet.
Diese Investition baut auf der bestehenden Präsenz von Roche in den USA auf, wo das Unternehmen in den letzten zehn Jahren 11 Milliarden USD investiert hat und über 25.000 Mitarbeiter an mehreren Genentech- und Diagnostikstandorten beschäftigt. Die neue Einrichtung stellt das Engagement von Roche dar, die langjährige Partnerschaft mit der Harvard University zu stärken und seinen Fußabdruck im Gesundheitsökosystem von Boston zu erweitern.
- Major expansion into Boston biotech hub with potential for 500 new jobs
- Strategic partnership with Harvard University strengthening R&D capabilities
- Investment in AI and data science for accelerated drug discovery
- Establishment of new CVRM research hub
- None.
- The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development
- Roche will be the first to join Harvard’s Enterprise Research Campus in Allston, taking a suite in the first phase of the project’s cutting-edge lab space
- Starting with a lease of 30’000 square feet, Roche intends to invest over the coming years into a research and development presence with eventually up to 500 employees
- Roche has long standing partnerships with Harvard University and others in the region and the center will expand Roche’s and Genentech’s presence in the vibrant Boston healthcare ecosystem
Basel, March 7, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will further strengthen the long-standing partnership in areas such as disease biology, engineering, and artificial intelligence / machine learning.
The Roche Genentech Innovation Center Boston will serve as Roche’s Cardiovascular, Renal, and Metabolism (CVRM) hub, establishing a significant end-to-end R&D presence in CVRM. It will also support some of Roche’s and Genentech’s efforts in AI and data science to accelerate drug discovery and development. The laboratories will be equipped for advanced research, and over time the center could employ up to 500 people. Manu Chakravarthy, SVP and Global Head of CVRM Product Development, will be the center’s site head.
With the new center, Roche and Genentech are expanding their presence within the Greater Boston innovation ecosystem, leveraging local talent and anchoring an entrepreneurial hub at Harvard’s Enterprise Research Campus. This new investment highlights Roche's dedication to advancing healthcare through academic and scientific collaboration and will serve to strengthen an existing relationship between Harvard and Roche that has been in place for well over a decade. These drug discovery efforts have included work to combat antibiotic resistant bacteria as well as the use of AI in cancer research to identify targeted approaches to treatment and to analyse the effectiveness of new cancer drugs in clinical trials.
Roche CEO Thomas Schinecker:
“Our new innovation center builds upon our long-standing collaboration with Harvard and enables us to leverage the exceptional talent in the Boston area. By investing in a new Cardiovascular, Renal, and Metabolism center of excellence, along with data science and AI capabilities at this strategic location, we aim to accelerate Roche`s and Genentech`s research efforts and leverage the Boston innovation ecosystem. Roche has a significant presence in the US and this new center is one of a number of research and manufacturing investments that Roche is making in the US through Genentech and Diagnostics.”
Alan Garber, President of Harvard University:
"In a region grounded in innovation in the sciences and health, when leading biomedical companies and research universities work together, breakthroughs follow. We are delighted that the Roche Genentech Innovation Center will launch the first phase of the Enterprise Research Campus. Building on an already strong and extensive partnership, the new Center will bring new talent and new opportunities to pursue our shared commitment to discovery for the advancement of human health."
Maura Healey, Governor of Massachusetts:
"Massachusetts is a global leader in the life sciences in large part because of innovative public-private partnerships like the one that led to the new Roche Genentech Innovation Center Boston at Harvard. I reauthorized our Life Sciences Initiative so that we can continue to support collaborations between leading institutions and companies that spur scientific discovery and create high-quality jobs. Together, we'll continue to grow Massachusetts' economy and help patients across the world."
Michelle Wu, Mayor of Boston:
“Roche’s decision to bring the new Roche Genentech Innovation Center to Allston is a powerful testament to the strength of Boston and Massachusetts as the global hub for life sciences and a major milestone for the Enterprise Research Campus and for this vibrant neighborhood. Our city welcomes expanding companies both homegrown and from across the world as the best place to source talent anywhere in the United States. We are excited for the great jobs and progress this represents for our city.”
Roche has the entire pharma and diagnostics value chain in the United States with four Genentech sites spanning R&D, production and distribution in its pharmaceutical division and seven sites focused on R&D and manufacturing in Diagnostics.
Roche has a significant footprint in the US with more than 25,000 employees, invested USD11 billion in the United States in the last 10 years and we will continue investing in the US going forward.
About the Enterprise Research Campus
Harvard’s Enterprise Research Campus, the first phase of which is underway and developed by Tishman Speyer and Breakthrough Properties, has been intentionally designed to foster innovation and collaboration. Located adjacent to Harvard’s Science and Engineering Complex and near Harvard Business School, the ERC will be a dynamic mixed-use development integrating research and laboratory space, residential buildings, a hotel, conference center, retail units, and a variety of community-centered outdoor spaces. The first phase of construction is expected to be complete in 2026.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Nina Mählitz Phone: +41 79 327 54 74 | Kirti Pandey Phone: +49 172 6367262 |
| Yvette Petillon Phone: +41 79 961 92 50 | Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
FAQ
How many jobs will the new Roche Genentech Innovation Center Boston (RHHBY) create?
What is the size of Roche's (RHHBY) initial lease at Harvard's Enterprise Research Campus?
How much has Roche (RHHBY) invested in the United States over the past decade?
What will be the main research focus of the new Roche (RHHBY) center in Boston?
